Advances in the field of cannabinoid–opioid cross‐talk

10.1016/S0091-3057(01)00578-0

10.1016/j.tips.2005.11.003

10.1007/s00213-002-1144-9

10.1042/bj3120637

10.1016/S0306-4522(01)00210-X

Braida D, 2001, Intracerebral self‐administration of the cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system, Eur J Pharmacol, 413, 227, 10.1016/S0014-2999(01)00766-X

10.1124/mol.60.1.155

10.1007/s002130100875

10.1523/JNEUROSCI.4403-06.2007

10.1038/sj.npp.1300848

10.1038/sj.bjp.0705882

10.1046/j.1460-9568.2003.02409.x

10.1007/BF02245916

10.1016/j.lfs.2003.09.038

10.1615/CritRevNeurobiol.v16.i12.170

10.1016/S1074-7427(03)00006-6

10.1016/j.nlm.2003.09.003

10.1007/s00213-003-1422-1

10.1016/j.tips.2005.06.002

10.1016/S0014-2999(02)02483-4

Devane WA, 1988, Determination and characterization of a cannabinoid receptor in rat brain, Mol Pharmacol, 34, 605

10.1038/sj.npp.1301127

Fan F, 1994, Development of cross‐tolerance between delta 9‐tetrahydrocannabinol, CP 55,940 and WIN 55,212, J Pharmacol Exp Ther, 271, 1383

10.1016/j.neuropharm.2005.01.022

10.1046/j.1460-9568.2003.02607.x

10.1016/j.brainresrev.2006.05.003

10.1111/j.1460-9568.2007.05470.x

Felder CC, 1992, Cannabinoid agonists stimulate both receptor‐ and non‐receptor‐mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones, Mol Pharmacol, 42, 838

10.1016/S0304-3940(97)00278-4

Fride E, 2003, Molecular Biology of Drug Addiction, 173

10.1046/j.1471-4159.1996.67031309.x

10.1523/JNEUROSCI.22-03-01146.2002

10.1016/S0376-8716(01)00186-7

10.1016/S0091-3057(03)00115-1

10.1080/1355621031000117383

10.1152/jn.2000.84.5.2356

10.1073/pnas.87.5.1932

10.1038/325445a0

10.1523/JNEUROSCI.20-07-02470.2000

10.1152/jn.2001.85.1.72

10.1002/(SICI)1098-2396(200007)37:1<71::AID-SYN8>3.0.CO;2-K

10.1016/0166-2236(90)90124-S

Howlett AC, 1984, Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes, Mol Pharmacol, 26, 532

10.1038/sj.bjp.0702228

10.1073/pnas.96.24.14136

10.1016/j.brainres.2005.09.015

10.1007/s00213-003-1693-6

10.1111/j.1460-9568.2004.03428.x

10.1007/BF00497855

10.1007/BF02071128

Kieffer BL, 2003, Molecular Biology of Drug Addiction, 3

10.1016/S0028-3908(01)00039-9

10.1126/science.283.5400.401

Lichtman AH, 2001, Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)‐tetrahydrocannabinol and morphine‐dependent mice, J Pharmacol Exp Ther, 298, 1007

10.1016/j.brainres.2005.08.002

10.1016/S0163-7258(02)00254-1

Maldonado R, 1992, Role of different brain structures in the expression of the physical morphine withdrawal syndrome, J Pharmacol Exp Ther, 261, 669

10.1016/j.euroneuro.2003.08.001

10.1016/j.tins.2006.01.008

10.1016/0166-2236(95)93946-U

10.1016/S0006-8993(99)01756-4

10.1046/j.1471-4159.2000.0752080.x

10.1097/01.wnr.0000126217.87116.8c

10.1152/jn.00855.2004

10.1016/S0091-3057(02)01041-9

10.1046/j.1460-9568.2000.00287.x

10.1038/sj.bjp.0703990

10.1016/S0278-5846(00)00119-6

10.1523/JNEUROSCI.4503-03.2004

Menard DP, 1996, A calcitonin gene‐related peptide receptor antagonist prevents the development of tolerance to spinal morphine analgesia, J Neurosci, 16, 2342, 10.1523/JNEUROSCI.16-07-02342.1996

10.1038/sj.npp.1300957

10.1006/bbrc.2002.6635

10.1016/0006-8993(82)90504-2

10.1038/365061a0

Navarro M, 2001, Functional interaction between opioid and cannabinoid receptors in drug self‐administration, J Neurosci, 21, 5344, 10.1523/JNEUROSCI.21-14-05344.2001

10.1097/00001756-199810260-00012

10.1016/S0014-2999(03)01455-9

10.1038/nature05726

Onaivi ES, 1990, Pharmacological characterization of cannabinoids in the elevated plus maze, J Pharmacol Exp Ther, 253, 1002

10.1124/pr.58.3.2

10.1111/j.1476-5381.1993.tb13989.x

10.1016/j.neuroscience.2004.05.015

10.1046/j.1460-9568.2002.02019.x

10.1016/j.biopsych.2004.05.006

10.1016/S0014-2999(01)01056-1

10.1016/S0006-8993(01)02158-8

10.1038/sj.bjp.0703655

10.1038/sj.bjp.0706757

10.1016/0165-0173(93)90013-P

10.1124/jpet.102.047928

10.1126/science.276.5321.2050

Rodríguez de Fonseca F, 1996, Corticotropin‐releasing factor (CRF) antagonist [D‐Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU‐210 on defensive‐withdrawal behavior in rats, J Pharmacol Exp Ther, 276, 56

10.1016/S0376-8716(98)00036-2

10.1016/S0091-3057(97)00485-1

10.1016/S0024-3205(00)00547-6

10.1016/S0006-8993(96)00941-9

10.1046/j.0953-816x.2001.01709.x

10.1097/00001756-200112040-00017

10.1016/S0165-6147(00)01805-8

10.1016/j.neuropharm.2006.05.019

10.1073/pnas.72.8.3092

10.1038/sj.npp.1300770

10.1046/j.1471-4159.1999.0732447.x

Smith PB, 1994, Interactions between delta 9‐tetrahydrocannabinol and kappa opioids in mice, J Pharmacol Exp Ther, 268, 1381

10.1124/jpet.102.047928

10.1016/j.biopsych.2006.03.073

10.1038/sj.bjp.0705932

10.1126/science.276.5321.2048

10.1016/0014-2999(94)90003-5

10.1016/j.pain.2006.07.008

10.1016/j.neuroscience.2007.02.031

10.1046/j.1460-9568.2000.00971.x

10.1038/sj.bjp.0704479

10.1111/j.1460-9568.2004.03278.x

Valverde O, 2000, Cannabinoid withdrawal syndrome is reduced in pre‐proenkephalin knock‐out mice, J Neurosci, 20, 9284, 10.1523/JNEUROSCI.20-24-09284.2000

10.1046/j.0953-816x.2001.01558.x

Valverde O, 2004, Involvement of the endogenous opioid system in cannabinoid responses, Curr Med Chem, 4, 183

10.1007/s002130000493

10.1126/science.1115740

10.1016/S0006-8993(98)00766-5

10.1016/0028-3908(95)00032-2

Vigano D, 2005, Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems, Psychopharmacology (Berl), 182, 527, 10.1007/s00213-005-0114-4

10.1111/j.1460-9568.2004.03645.x

10.1016/S0376-8716(97)01342-2

10.1126/science.1063545

10.1097/00008877-200605000-00004

10.1523/JNEUROSCI.21-23-09499.2001